Ainos Inc.宣布对HIV+病人口服激素进行VELDONA临床试验,定于国家台湾大学医院开始。 Ainos Inc. announces VELDONA® clinical trial for oral warts in HIV+ patients, set to begin at National Taiwan University Hospital.

2024年9月20日, Ainos Inc. 宣布Water Tower Research已发表关于VELDONA临床试验的说明, On September 20, 2024, Ainos, Inc. announced that Water Tower Research has released a note on its VELDONA® clinical trial, targeting oral warts in HIV+ patients. 该试验将于2024年11月在台湾国立大学医院开始,将涉及40名受试者,目标是在24周内将表面积减少75%. Set to begin by November 2024 at National Taiwan University Hospital, the trial will involve 40 subjects and aims for a 75% reduction in wart surface area over 24 weeks. 美国食品和药物管理局已授予VELDONA®孤儿药物称号,解决了这一患者群体对治疗选择的重大需求. VELDONA® has received Orphan Drug Designation from the FDA, addressing a significant need for treatment options in this patient group.